Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Tuberous Sclerosis 3

Interventions

Everolimus 18Sirolimus 15Cannabidiol 5radiprodil 3ganaxolone 3Vigabatrin 3Activator Appliances 3Melatonin 2exemestane 1dactolisib 1carbon-11 acetate 1Surveys and Questionnaires 1Simvastatin 1Sertraline 1Selective Serotonin Reuptake Inhibitors 1Propranolol 1Itraconazole 1Injections 1Fluid Therapy 1Doxycycline 1Curcumin 1Carbamazepine 1Calcitriol 1Aspirin 1Anticonvulsants 1Actigraphy 1Acceptance and Commitment Therapy 12-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Tuberous Sclerosis × ganaxolone × Clear all
NCT05604170 2025-10-01

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

Marinus Pharmaceuticals

Phase 3 Terminated
117 enrolled 11 charts

Tuberous Sclerosis

NCT05323734 2025-07-11

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

Marinus Pharmaceuticals

Phase 3 Completed
129 enrolled 13 charts

Tuberous Sclerosis

NCT04285346 2023-04-04

TSC

Marinus Pharmaceuticals

Phase 2 Completed
23 enrolled 9 charts

Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡